enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Etranacogene dezaparvovec - Wikipedia

   en.wikipedia.org/wiki/Etranacogene_dezaparvovec

   KEGG. D12500. Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of hemophilia B. [ 5 ][ 6 ][ 7 ] Etranacogene dezaparvovec is an adeno-associated virus vector-based gene therapy which consists of a viral vector carrying a gene for clotting Factor IX. [ 7 ] The gene is expressed in the liver ...

3. Haemophilia - Wikipedia

   en.wikipedia.org/wiki/Haemophilia

   Haemophilia. Haemophilia (British English), or hemophilia (American English) [6] (from Ancient Greek αἷμα (haîma) 'blood' and φιλία (philía) 'love of'), [7] is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. [2][3] This results in people bleeding for a ...

4. FDA Approves Pfizer's Second Hemophilia Drug With Six Months

   www.aol.com/fda-approves-pfizers-second...

   Vandana Singh. October 14, 2024 at 9:35 AM. FDA Approves Pfizer's Second Hemophilia Drug With Six Months. On Friday, the FDA approved Pfizer Inc’s (NYSE: PFE) Hympavzi (marstacimab-hncq) for ...

5. Efanesoctocog alfa - Wikipedia

   en.wikipedia.org/wiki/Efanesoctocog_alfa

   Formula. C13690H20958N3682O4376S136. Molar mass. 311501.81 g·mol −1. Efanesoctocog alfa, sold under the brand name Altuviiio, is a medication used for the treatment of hemophilia A (congenital factor VIII deficiency). [ 1 ][ 4 ] Efanesoctocog alfa was approved for medical use in the United States in February 2023. [ 1 ][ 4 ][ 5 ][ 6 ]

6. Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy ...

   www.aol.com/news/pfizer-resumes-dosing-phase-3...

   Pfizer Inc (NASDAQ: PFE) and its partner Sangamo Therapeutics Inc (NASDAQ: SGMO) have reopened enrollment in phase 3 AFFINE study hemophilia A gene therapy trial. Trial sites will begin to resume ...

7. Australia's CSL prices hemophilia gene therapy at $3.5 million

   www.aol.com/news/fda-approves-csls-gene-therapy...

   (Reuters) -Australian drugmaker CSL Ltd on Tuesday set the list price of its one-time gene therapy for hemophilia B at $3.5 million, making it the world's most expensive treatment, following its ...

8. Emicizumab - Wikipedia

   en.wikipedia.org/wiki/Emicizumab

   Molar mass. 145 639.02 g·mol −1. Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). [4] A Phase I clinical trial found that it was well tolerated by healthy subjects.

9. A hemophilia drug that just won FDA approval pegs a one-time ...

   www.aol.com/news/hemophilia-drug-just-won-fda...

   There’s a new one-time treatment for Hemophilia B patients in the market, but it comes with an obscene price tag. A hemophilia drug that just won FDA approval pegs a one-time $3.5 million vial ...